nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadobenate Dimeglumine—Cardiac failure congestive—Cisplatin—esophageal cancer	0.00498	0.00498	CcSEcCtD
Gadobenate Dimeglumine—Burning sensation—Methotrexate—esophageal cancer	0.00492	0.00492	CcSEcCtD
Gadobenate Dimeglumine—Paralysis—Methotrexate—esophageal cancer	0.00492	0.00492	CcSEcCtD
Gadobenate Dimeglumine—Blood bilirubin increased—Capecitabine—esophageal cancer	0.00485	0.00485	CcSEcCtD
Gadobenate Dimeglumine—Lung disorder—Methotrexate—esophageal cancer	0.00482	0.00482	CcSEcCtD
Gadobenate Dimeglumine—Cyanosis—Methotrexate—esophageal cancer	0.00482	0.00482	CcSEcCtD
Gadobenate Dimeglumine—Hearing impaired—Capecitabine—esophageal cancer	0.00482	0.00482	CcSEcCtD
Gadobenate Dimeglumine—Inflammation—Capecitabine—esophageal cancer	0.00473	0.00473	CcSEcCtD
Gadobenate Dimeglumine—Anaphylactoid reaction—Cisplatin—esophageal cancer	0.00467	0.00467	CcSEcCtD
Gadobenate Dimeglumine—Blood pressure increased—Capecitabine—esophageal cancer	0.00459	0.00459	CcSEcCtD
Gadobenate Dimeglumine—Phosphatase alkaline increased—Capecitabine—esophageal cancer	0.00459	0.00459	CcSEcCtD
Gadobenate Dimeglumine—Pulmonary embolism—Capecitabine—esophageal cancer	0.00459	0.00459	CcSEcCtD
Gadobenate Dimeglumine—Stupor—Methotrexate—esophageal cancer	0.00457	0.00457	CcSEcCtD
Gadobenate Dimeglumine—Injection site reaction—Capecitabine—esophageal cancer	0.00456	0.00456	CcSEcCtD
Gadobenate Dimeglumine—Hyponatraemia—Cisplatin—esophageal cancer	0.00454	0.00454	CcSEcCtD
Gadobenate Dimeglumine—Depressed level of consciousness—Capecitabine—esophageal cancer	0.00443	0.00443	CcSEcCtD
Gadobenate Dimeglumine—Urinary incontinence—Capecitabine—esophageal cancer	0.00443	0.00443	CcSEcCtD
Gadobenate Dimeglumine—Face oedema—Cisplatin—esophageal cancer	0.00436	0.00436	CcSEcCtD
Gadobenate Dimeglumine—Blood creatinine increased—Cisplatin—esophageal cancer	0.00423	0.00423	CcSEcCtD
Gadobenate Dimeglumine—Ecchymosis—Capecitabine—esophageal cancer	0.00415	0.00415	CcSEcCtD
Gadobenate Dimeglumine—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.00407	0.00407	CcSEcCtD
Gadobenate Dimeglumine—Nasopharyngitis—Cisplatin—esophageal cancer	0.00404	0.00404	CcSEcCtD
Gadobenate Dimeglumine—Abnormal vision—Capecitabine—esophageal cancer	0.004	0.004	CcSEcCtD
Gadobenate Dimeglumine—Extravasation—Methotrexate—esophageal cancer	0.00391	0.00391	CcSEcCtD
Gadobenate Dimeglumine—Ear pain—Capecitabine—esophageal cancer	0.0039	0.0039	CcSEcCtD
Gadobenate Dimeglumine—Proteinuria—Methotrexate—esophageal cancer	0.00389	0.00389	CcSEcCtD
Gadobenate Dimeglumine—Phlebitis—Capecitabine—esophageal cancer	0.00387	0.00387	CcSEcCtD
Gadobenate Dimeglumine—Protein urine present—Methotrexate—esophageal cancer	0.00383	0.00383	CcSEcCtD
Gadobenate Dimeglumine—Blood alkaline phosphatase increased—Capecitabine—esophageal cancer	0.00383	0.00383	CcSEcCtD
Gadobenate Dimeglumine—Hepatic function abnormal—Capecitabine—esophageal cancer	0.00381	0.00381	CcSEcCtD
Gadobenate Dimeglumine—Swelling—Capecitabine—esophageal cancer	0.00377	0.00377	CcSEcCtD
Gadobenate Dimeglumine—Hyperbilirubinaemia—Methotrexate—esophageal cancer	0.00376	0.00376	CcSEcCtD
Gadobenate Dimeglumine—Abdominal discomfort—Cisplatin—esophageal cancer	0.00374	0.00374	CcSEcCtD
Gadobenate Dimeglumine—Deafness—Capecitabine—esophageal cancer	0.00372	0.00372	CcSEcCtD
Gadobenate Dimeglumine—Eye pain—Capecitabine—esophageal cancer	0.00369	0.00369	CcSEcCtD
Gadobenate Dimeglumine—Hepatic enzyme increased—Methotrexate—esophageal cancer	0.00361	0.00361	CcSEcCtD
Gadobenate Dimeglumine—Inflammation—Methotrexate—esophageal cancer	0.00352	0.00352	CcSEcCtD
Gadobenate Dimeglumine—Atrial fibrillation—Capecitabine—esophageal cancer	0.00351	0.00351	CcSEcCtD
Gadobenate Dimeglumine—Thirst—Capecitabine—esophageal cancer	0.0035	0.0035	CcSEcCtD
Gadobenate Dimeglumine—Dermatitis bullous—Capecitabine—esophageal cancer	0.00348	0.00348	CcSEcCtD
Gadobenate Dimeglumine—Respiratory failure—Methotrexate—esophageal cancer	0.00348	0.00348	CcSEcCtD
Gadobenate Dimeglumine—Renal failure—Cisplatin—esophageal cancer	0.00342	0.00342	CcSEcCtD
Gadobenate Dimeglumine—Pulmonary embolism—Methotrexate—esophageal cancer	0.00342	0.00342	CcSEcCtD
Gadobenate Dimeglumine—Cardiac failure—Capecitabine—esophageal cancer	0.00341	0.00341	CcSEcCtD
Gadobenate Dimeglumine—Conjunctivitis—Cisplatin—esophageal cancer	0.00338	0.00338	CcSEcCtD
Gadobenate Dimeglumine—Hyponatraemia—Capecitabine—esophageal cancer	0.00334	0.00334	CcSEcCtD
Gadobenate Dimeglumine—Pain in extremity—Capecitabine—esophageal cancer	0.00333	0.00333	CcSEcCtD
Gadobenate Dimeglumine—Depressed level of consciousness—Methotrexate—esophageal cancer	0.0033	0.0033	CcSEcCtD
Gadobenate Dimeglumine—Migraine—Capecitabine—esophageal cancer	0.00328	0.00328	CcSEcCtD
Gadobenate Dimeglumine—Face oedema—Capecitabine—esophageal cancer	0.00321	0.00321	CcSEcCtD
Gadobenate Dimeglumine—Bradycardia—Cisplatin—esophageal cancer	0.00318	0.00318	CcSEcCtD
Gadobenate Dimeglumine—Cardiac arrest—Capecitabine—esophageal cancer	0.00317	0.00317	CcSEcCtD
Gadobenate Dimeglumine—Blood creatinine increased—Capecitabine—esophageal cancer	0.00312	0.00312	CcSEcCtD
Gadobenate Dimeglumine—Ecchymosis—Methotrexate—esophageal cancer	0.00309	0.00309	CcSEcCtD
Gadobenate Dimeglumine—Urinary tract disorder—Cisplatin—esophageal cancer	0.00309	0.00309	CcSEcCtD
Gadobenate Dimeglumine—Liver function test abnormal—Capecitabine—esophageal cancer	0.00307	0.00307	CcSEcCtD
Gadobenate Dimeglumine—Connective tissue disorder—Cisplatin—esophageal cancer	0.00307	0.00307	CcSEcCtD
Gadobenate Dimeglumine—Urethral disorder—Cisplatin—esophageal cancer	0.00306	0.00306	CcSEcCtD
Gadobenate Dimeglumine—Pulmonary oedema—Methotrexate—esophageal cancer	0.00304	0.00304	CcSEcCtD
Gadobenate Dimeglumine—Visual impairment—Cisplatin—esophageal cancer	0.00301	0.00301	CcSEcCtD
Gadobenate Dimeglumine—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.003	0.003	CcSEcCtD
Gadobenate Dimeglumine—Nasopharyngitis—Capecitabine—esophageal cancer	0.00298	0.00298	CcSEcCtD
Gadobenate Dimeglumine—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00294	0.00294	CcSEcCtD
Gadobenate Dimeglumine—Eye disorder—Cisplatin—esophageal cancer	0.00292	0.00292	CcSEcCtD
Gadobenate Dimeglumine—Tinnitus—Cisplatin—esophageal cancer	0.00291	0.00291	CcSEcCtD
Gadobenate Dimeglumine—Flushing—Cisplatin—esophageal cancer	0.0029	0.0029	CcSEcCtD
Gadobenate Dimeglumine—Cardiac disorder—Cisplatin—esophageal cancer	0.0029	0.0029	CcSEcCtD
Gadobenate Dimeglumine—Asthma—Capecitabine—esophageal cancer	0.00288	0.00288	CcSEcCtD
Gadobenate Dimeglumine—Bronchospasm—Capecitabine—esophageal cancer	0.00283	0.00283	CcSEcCtD
Gadobenate Dimeglumine—Immune system disorder—Cisplatin—esophageal cancer	0.00282	0.00282	CcSEcCtD
Gadobenate Dimeglumine—Mediastinal disorder—Cisplatin—esophageal cancer	0.00282	0.00282	CcSEcCtD
Gadobenate Dimeglumine—Arrhythmia—Cisplatin—esophageal cancer	0.00279	0.00279	CcSEcCtD
Gadobenate Dimeglumine—Bronchitis—Capecitabine—esophageal cancer	0.00277	0.00277	CcSEcCtD
Gadobenate Dimeglumine—Abdominal discomfort—Capecitabine—esophageal cancer	0.00276	0.00276	CcSEcCtD
Gadobenate Dimeglumine—Erythema—Cisplatin—esophageal cancer	0.00272	0.00272	CcSEcCtD
Gadobenate Dimeglumine—Malnutrition—Cisplatin—esophageal cancer	0.00272	0.00272	CcSEcCtD
Gadobenate Dimeglumine—Muscle spasms—Cisplatin—esophageal cancer	0.00262	0.00262	CcSEcCtD
Gadobenate Dimeglumine—Hyperglycaemia—Capecitabine—esophageal cancer	0.0026	0.0026	CcSEcCtD
Gadobenate Dimeglumine—Infestation—Capecitabine—esophageal cancer	0.00257	0.00257	CcSEcCtD
Gadobenate Dimeglumine—Infestation NOS—Capecitabine—esophageal cancer	0.00257	0.00257	CcSEcCtD
Gadobenate Dimeglumine—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.00256	0.00256	CcSEcCtD
Gadobenate Dimeglumine—Tremor—Cisplatin—esophageal cancer	0.00255	0.00255	CcSEcCtD
Gadobenate Dimeglumine—Ill-defined disorder—Cisplatin—esophageal cancer	0.00252	0.00252	CcSEcCtD
Gadobenate Dimeglumine—Renal failure—Capecitabine—esophageal cancer	0.00252	0.00252	CcSEcCtD
Gadobenate Dimeglumine—Anaemia—Cisplatin—esophageal cancer	0.00251	0.00251	CcSEcCtD
Gadobenate Dimeglumine—Urinary tract infection—Capecitabine—esophageal cancer	0.00249	0.00249	CcSEcCtD
Gadobenate Dimeglumine—Conjunctivitis—Capecitabine—esophageal cancer	0.00249	0.00249	CcSEcCtD
Gadobenate Dimeglumine—Malaise—Cisplatin—esophageal cancer	0.00245	0.00245	CcSEcCtD
Gadobenate Dimeglumine—Haematuria—Capecitabine—esophageal cancer	0.00245	0.00245	CcSEcCtD
Gadobenate Dimeglumine—Leukopenia—Cisplatin—esophageal cancer	0.00244	0.00244	CcSEcCtD
Gadobenate Dimeglumine—Bradycardia—Capecitabine—esophageal cancer	0.00235	0.00235	CcSEcCtD
Gadobenate Dimeglumine—Myalgia—Cisplatin—esophageal cancer	0.00232	0.00232	CcSEcCtD
Gadobenate Dimeglumine—Rhinitis—Capecitabine—esophageal cancer	0.00231	0.00231	CcSEcCtD
Gadobenate Dimeglumine—Anxiety—Cisplatin—esophageal cancer	0.00231	0.00231	CcSEcCtD
Gadobenate Dimeglumine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.0023	0.0023	CcSEcCtD
Gadobenate Dimeglumine—Hypoaesthesia—Capecitabine—esophageal cancer	0.00229	0.00229	CcSEcCtD
Gadobenate Dimeglumine—Liver function test abnormal—Methotrexate—esophageal cancer	0.00229	0.00229	CcSEcCtD
Gadobenate Dimeglumine—Discomfort—Cisplatin—esophageal cancer	0.00229	0.00229	CcSEcCtD
Gadobenate Dimeglumine—Urinary tract disorder—Capecitabine—esophageal cancer	0.00227	0.00227	CcSEcCtD
Gadobenate Dimeglumine—Oedema peripheral—Capecitabine—esophageal cancer	0.00227	0.00227	CcSEcCtD
Gadobenate Dimeglumine—Connective tissue disorder—Capecitabine—esophageal cancer	0.00226	0.00226	CcSEcCtD
Gadobenate Dimeglumine—Urethral disorder—Capecitabine—esophageal cancer	0.00226	0.00226	CcSEcCtD
Gadobenate Dimeglumine—Anaphylactic shock—Cisplatin—esophageal cancer	0.00222	0.00222	CcSEcCtD
Gadobenate Dimeglumine—Visual impairment—Capecitabine—esophageal cancer	0.00222	0.00222	CcSEcCtD
Gadobenate Dimeglumine—Infection—Cisplatin—esophageal cancer	0.00221	0.00221	CcSEcCtD
Gadobenate Dimeglumine—Nervous system disorder—Cisplatin—esophageal cancer	0.00218	0.00218	CcSEcCtD
Gadobenate Dimeglumine—Tachycardia—Cisplatin—esophageal cancer	0.00217	0.00217	CcSEcCtD
Gadobenate Dimeglumine—Skin disorder—Cisplatin—esophageal cancer	0.00216	0.00216	CcSEcCtD
Gadobenate Dimeglumine—Eye disorder—Capecitabine—esophageal cancer	0.00215	0.00215	CcSEcCtD
Gadobenate Dimeglumine—Tinnitus—Capecitabine—esophageal cancer	0.00215	0.00215	CcSEcCtD
Gadobenate Dimeglumine—Hyperhidrosis—Cisplatin—esophageal cancer	0.00215	0.00215	CcSEcCtD
Gadobenate Dimeglumine—Asthma—Methotrexate—esophageal cancer	0.00214	0.00214	CcSEcCtD
Gadobenate Dimeglumine—Flushing—Capecitabine—esophageal cancer	0.00214	0.00214	CcSEcCtD
Gadobenate Dimeglumine—Cardiac disorder—Capecitabine—esophageal cancer	0.00214	0.00214	CcSEcCtD
Gadobenate Dimeglumine—Angiopathy—Capecitabine—esophageal cancer	0.00209	0.00209	CcSEcCtD
Gadobenate Dimeglumine—Immune system disorder—Capecitabine—esophageal cancer	0.00208	0.00208	CcSEcCtD
Gadobenate Dimeglumine—Mediastinal disorder—Capecitabine—esophageal cancer	0.00208	0.00208	CcSEcCtD
Gadobenate Dimeglumine—Hypotension—Cisplatin—esophageal cancer	0.00207	0.00207	CcSEcCtD
Gadobenate Dimeglumine—Chills—Capecitabine—esophageal cancer	0.00207	0.00207	CcSEcCtD
Gadobenate Dimeglumine—Arrhythmia—Capecitabine—esophageal cancer	0.00206	0.00206	CcSEcCtD
Gadobenate Dimeglumine—Abdominal discomfort—Methotrexate—esophageal cancer	0.00205	0.00205	CcSEcCtD
Gadobenate Dimeglumine—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00202	0.00202	CcSEcCtD
Gadobenate Dimeglumine—Mental disorder—Capecitabine—esophageal cancer	0.00202	0.00202	CcSEcCtD
Gadobenate Dimeglumine—Malnutrition—Capecitabine—esophageal cancer	0.00201	0.00201	CcSEcCtD
Gadobenate Dimeglumine—Erythema—Capecitabine—esophageal cancer	0.00201	0.00201	CcSEcCtD
Gadobenate Dimeglumine—Paraesthesia—Cisplatin—esophageal cancer	0.00199	0.00199	CcSEcCtD
Gadobenate Dimeglumine—Dyspnoea—Cisplatin—esophageal cancer	0.00198	0.00198	CcSEcCtD
Gadobenate Dimeglumine—Dysgeusia—Capecitabine—esophageal cancer	0.00196	0.00196	CcSEcCtD
Gadobenate Dimeglumine—Back pain—Capecitabine—esophageal cancer	0.00194	0.00194	CcSEcCtD
Gadobenate Dimeglumine—Muscle spasms—Capecitabine—esophageal cancer	0.00193	0.00193	CcSEcCtD
Gadobenate Dimeglumine—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00192	0.00192	CcSEcCtD
Gadobenate Dimeglumine—Infestation NOS—Methotrexate—esophageal cancer	0.00191	0.00191	CcSEcCtD
Gadobenate Dimeglumine—Infestation—Methotrexate—esophageal cancer	0.00191	0.00191	CcSEcCtD
Gadobenate Dimeglumine—Pain—Cisplatin—esophageal cancer	0.0019	0.0019	CcSEcCtD
Gadobenate Dimeglumine—Tremor—Capecitabine—esophageal cancer	0.00188	0.00188	CcSEcCtD
Gadobenate Dimeglumine—Renal failure—Methotrexate—esophageal cancer	0.00188	0.00188	CcSEcCtD
Gadobenate Dimeglumine—Ill-defined disorder—Capecitabine—esophageal cancer	0.00186	0.00186	CcSEcCtD
Gadobenate Dimeglumine—Conjunctivitis—Methotrexate—esophageal cancer	0.00186	0.00186	CcSEcCtD
Gadobenate Dimeglumine—Anaemia—Capecitabine—esophageal cancer	0.00185	0.00185	CcSEcCtD
Gadobenate Dimeglumine—Sweating—Methotrexate—esophageal cancer	0.00183	0.00183	CcSEcCtD
Gadobenate Dimeglumine—Feeling abnormal—Cisplatin—esophageal cancer	0.00183	0.00183	CcSEcCtD
Gadobenate Dimeglumine—Haematuria—Methotrexate—esophageal cancer	0.00182	0.00182	CcSEcCtD
Gadobenate Dimeglumine—Malaise—Capecitabine—esophageal cancer	0.00181	0.00181	CcSEcCtD
Gadobenate Dimeglumine—Syncope—Capecitabine—esophageal cancer	0.0018	0.0018	CcSEcCtD
Gadobenate Dimeglumine—Leukopenia—Capecitabine—esophageal cancer	0.0018	0.0018	CcSEcCtD
Gadobenate Dimeglumine—Palpitations—Capecitabine—esophageal cancer	0.00177	0.00177	CcSEcCtD
Gadobenate Dimeglumine—Loss of consciousness—Capecitabine—esophageal cancer	0.00176	0.00176	CcSEcCtD
Gadobenate Dimeglumine—Body temperature increased—Cisplatin—esophageal cancer	0.00176	0.00176	CcSEcCtD
Gadobenate Dimeglumine—Cough—Capecitabine—esophageal cancer	0.00175	0.00175	CcSEcCtD
Gadobenate Dimeglumine—Hypertension—Capecitabine—esophageal cancer	0.00173	0.00173	CcSEcCtD
Gadobenate Dimeglumine—Arthralgia—Capecitabine—esophageal cancer	0.00171	0.00171	CcSEcCtD
Gadobenate Dimeglumine—Myalgia—Capecitabine—esophageal cancer	0.00171	0.00171	CcSEcCtD
Gadobenate Dimeglumine—Chest pain—Capecitabine—esophageal cancer	0.00171	0.00171	CcSEcCtD
Gadobenate Dimeglumine—Anxiety—Capecitabine—esophageal cancer	0.0017	0.0017	CcSEcCtD
Gadobenate Dimeglumine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.0017	0.0017	CcSEcCtD
Gadobenate Dimeglumine—Urinary tract disorder—Methotrexate—esophageal cancer	0.00169	0.00169	CcSEcCtD
Gadobenate Dimeglumine—Discomfort—Capecitabine—esophageal cancer	0.00169	0.00169	CcSEcCtD
Gadobenate Dimeglumine—Urethral disorder—Methotrexate—esophageal cancer	0.00168	0.00168	CcSEcCtD
Gadobenate Dimeglumine—Dry mouth—Capecitabine—esophageal cancer	0.00167	0.00167	CcSEcCtD
Gadobenate Dimeglumine—Visual impairment—Methotrexate—esophageal cancer	0.00165	0.00165	CcSEcCtD
Gadobenate Dimeglumine—Confusional state—Capecitabine—esophageal cancer	0.00165	0.00165	CcSEcCtD
Gadobenate Dimeglumine—Hypersensitivity—Cisplatin—esophageal cancer	0.00164	0.00164	CcSEcCtD
Gadobenate Dimeglumine—Infection—Capecitabine—esophageal cancer	0.00163	0.00163	CcSEcCtD
Gadobenate Dimeglumine—Shock—Capecitabine—esophageal cancer	0.00161	0.00161	CcSEcCtD
Gadobenate Dimeglumine—Nervous system disorder—Capecitabine—esophageal cancer	0.00161	0.00161	CcSEcCtD
Gadobenate Dimeglumine—Eye disorder—Methotrexate—esophageal cancer	0.0016	0.0016	CcSEcCtD
Gadobenate Dimeglumine—Tinnitus—Methotrexate—esophageal cancer	0.0016	0.0016	CcSEcCtD
Gadobenate Dimeglumine—Tachycardia—Capecitabine—esophageal cancer	0.0016	0.0016	CcSEcCtD
Gadobenate Dimeglumine—Asthenia—Cisplatin—esophageal cancer	0.00159	0.00159	CcSEcCtD
Gadobenate Dimeglumine—Cardiac disorder—Methotrexate—esophageal cancer	0.00159	0.00159	CcSEcCtD
Gadobenate Dimeglumine—Skin disorder—Capecitabine—esophageal cancer	0.00159	0.00159	CcSEcCtD
Gadobenate Dimeglumine—Hyperhidrosis—Capecitabine—esophageal cancer	0.00158	0.00158	CcSEcCtD
Gadobenate Dimeglumine—Angiopathy—Methotrexate—esophageal cancer	0.00156	0.00156	CcSEcCtD
Gadobenate Dimeglumine—Immune system disorder—Methotrexate—esophageal cancer	0.00155	0.00155	CcSEcCtD
Gadobenate Dimeglumine—Mediastinal disorder—Methotrexate—esophageal cancer	0.00155	0.00155	CcSEcCtD
Gadobenate Dimeglumine—Chills—Methotrexate—esophageal cancer	0.00154	0.00154	CcSEcCtD
Gadobenate Dimeglumine—Hypotension—Capecitabine—esophageal cancer	0.00153	0.00153	CcSEcCtD
Gadobenate Dimeglumine—Diarrhoea—Cisplatin—esophageal cancer	0.00152	0.00152	CcSEcCtD
Gadobenate Dimeglumine—Mental disorder—Methotrexate—esophageal cancer	0.0015	0.0015	CcSEcCtD
Gadobenate Dimeglumine—Erythema—Methotrexate—esophageal cancer	0.00149	0.00149	CcSEcCtD
Gadobenate Dimeglumine—Malnutrition—Methotrexate—esophageal cancer	0.00149	0.00149	CcSEcCtD
Gadobenate Dimeglumine—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00149	0.00149	CcSEcCtD
Gadobenate Dimeglumine—Paraesthesia—Capecitabine—esophageal cancer	0.00147	0.00147	CcSEcCtD
Gadobenate Dimeglumine—Dysgeusia—Methotrexate—esophageal cancer	0.00146	0.00146	CcSEcCtD
Gadobenate Dimeglumine—Dyspnoea—Capecitabine—esophageal cancer	0.00146	0.00146	CcSEcCtD
Gadobenate Dimeglumine—Back pain—Methotrexate—esophageal cancer	0.00144	0.00144	CcSEcCtD
Gadobenate Dimeglumine—Dyspepsia—Capecitabine—esophageal cancer	0.00144	0.00144	CcSEcCtD
Gadobenate Dimeglumine—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00141	0.00141	CcSEcCtD
Gadobenate Dimeglumine—Vomiting—Cisplatin—esophageal cancer	0.00141	0.00141	CcSEcCtD
Gadobenate Dimeglumine—Fatigue—Capecitabine—esophageal cancer	0.00141	0.00141	CcSEcCtD
Gadobenate Dimeglumine—Rash—Cisplatin—esophageal cancer	0.0014	0.0014	CcSEcCtD
Gadobenate Dimeglumine—Constipation—Capecitabine—esophageal cancer	0.0014	0.0014	CcSEcCtD
Gadobenate Dimeglumine—Pain—Capecitabine—esophageal cancer	0.0014	0.0014	CcSEcCtD
Gadobenate Dimeglumine—Dermatitis—Cisplatin—esophageal cancer	0.0014	0.0014	CcSEcCtD
Gadobenate Dimeglumine—Ill-defined disorder—Methotrexate—esophageal cancer	0.00139	0.00139	CcSEcCtD
Gadobenate Dimeglumine—Anaemia—Methotrexate—esophageal cancer	0.00138	0.00138	CcSEcCtD
Gadobenate Dimeglumine—Feeling abnormal—Capecitabine—esophageal cancer	0.00135	0.00135	CcSEcCtD
Gadobenate Dimeglumine—Malaise—Methotrexate—esophageal cancer	0.00135	0.00135	CcSEcCtD
Gadobenate Dimeglumine—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00134	0.00134	CcSEcCtD
Gadobenate Dimeglumine—Leukopenia—Methotrexate—esophageal cancer	0.00134	0.00134	CcSEcCtD
Gadobenate Dimeglumine—Nausea—Cisplatin—esophageal cancer	0.00132	0.00132	CcSEcCtD
Gadobenate Dimeglumine—Cough—Methotrexate—esophageal cancer	0.0013	0.0013	CcSEcCtD
Gadobenate Dimeglumine—Urticaria—Capecitabine—esophageal cancer	0.0013	0.0013	CcSEcCtD
Gadobenate Dimeglumine—Abdominal pain—Capecitabine—esophageal cancer	0.00129	0.00129	CcSEcCtD
Gadobenate Dimeglumine—Body temperature increased—Capecitabine—esophageal cancer	0.00129	0.00129	CcSEcCtD
Gadobenate Dimeglumine—Arthralgia—Methotrexate—esophageal cancer	0.00127	0.00127	CcSEcCtD
Gadobenate Dimeglumine—Chest pain—Methotrexate—esophageal cancer	0.00127	0.00127	CcSEcCtD
Gadobenate Dimeglumine—Myalgia—Methotrexate—esophageal cancer	0.00127	0.00127	CcSEcCtD
Gadobenate Dimeglumine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00126	0.00126	CcSEcCtD
Gadobenate Dimeglumine—Discomfort—Methotrexate—esophageal cancer	0.00126	0.00126	CcSEcCtD
Gadobenate Dimeglumine—Confusional state—Methotrexate—esophageal cancer	0.00123	0.00123	CcSEcCtD
Gadobenate Dimeglumine—Anaphylactic shock—Methotrexate—esophageal cancer	0.00122	0.00122	CcSEcCtD
Gadobenate Dimeglumine—Infection—Methotrexate—esophageal cancer	0.00121	0.00121	CcSEcCtD
Gadobenate Dimeglumine—Hypersensitivity—Capecitabine—esophageal cancer	0.00121	0.00121	CcSEcCtD
Gadobenate Dimeglumine—Nervous system disorder—Methotrexate—esophageal cancer	0.00119	0.00119	CcSEcCtD
Gadobenate Dimeglumine—Skin disorder—Methotrexate—esophageal cancer	0.00118	0.00118	CcSEcCtD
Gadobenate Dimeglumine—Hyperhidrosis—Methotrexate—esophageal cancer	0.00118	0.00118	CcSEcCtD
Gadobenate Dimeglumine—Asthenia—Capecitabine—esophageal cancer	0.00117	0.00117	CcSEcCtD
Gadobenate Dimeglumine—Pruritus—Capecitabine—esophageal cancer	0.00116	0.00116	CcSEcCtD
Gadobenate Dimeglumine—Hypotension—Methotrexate—esophageal cancer	0.00114	0.00114	CcSEcCtD
Gadobenate Dimeglumine—Diarrhoea—Capecitabine—esophageal cancer	0.00112	0.00112	CcSEcCtD
Gadobenate Dimeglumine—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00111	0.00111	CcSEcCtD
Gadobenate Dimeglumine—Paraesthesia—Methotrexate—esophageal cancer	0.00109	0.00109	CcSEcCtD
Gadobenate Dimeglumine—Dyspnoea—Methotrexate—esophageal cancer	0.00109	0.00109	CcSEcCtD
Gadobenate Dimeglumine—Somnolence—Methotrexate—esophageal cancer	0.00108	0.00108	CcSEcCtD
Gadobenate Dimeglumine—Dizziness—Capecitabine—esophageal cancer	0.00108	0.00108	CcSEcCtD
Gadobenate Dimeglumine—Dyspepsia—Methotrexate—esophageal cancer	0.00107	0.00107	CcSEcCtD
Gadobenate Dimeglumine—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00105	0.00105	CcSEcCtD
Gadobenate Dimeglumine—Fatigue—Methotrexate—esophageal cancer	0.00105	0.00105	CcSEcCtD
Gadobenate Dimeglumine—Pain—Methotrexate—esophageal cancer	0.00104	0.00104	CcSEcCtD
Gadobenate Dimeglumine—Vomiting—Capecitabine—esophageal cancer	0.00104	0.00104	CcSEcCtD
Gadobenate Dimeglumine—Rash—Capecitabine—esophageal cancer	0.00103	0.00103	CcSEcCtD
Gadobenate Dimeglumine—Dermatitis—Capecitabine—esophageal cancer	0.00103	0.00103	CcSEcCtD
Gadobenate Dimeglumine—Headache—Capecitabine—esophageal cancer	0.00103	0.00103	CcSEcCtD
Gadobenate Dimeglumine—Feeling abnormal—Methotrexate—esophageal cancer	0.001	0.001	CcSEcCtD
Gadobenate Dimeglumine—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000996	0.000996	CcSEcCtD
Gadobenate Dimeglumine—Nausea—Capecitabine—esophageal cancer	0.000972	0.000972	CcSEcCtD
Gadobenate Dimeglumine—Urticaria—Methotrexate—esophageal cancer	0.000968	0.000968	CcSEcCtD
Gadobenate Dimeglumine—Abdominal pain—Methotrexate—esophageal cancer	0.000963	0.000963	CcSEcCtD
Gadobenate Dimeglumine—Body temperature increased—Methotrexate—esophageal cancer	0.000963	0.000963	CcSEcCtD
Gadobenate Dimeglumine—Hypersensitivity—Methotrexate—esophageal cancer	0.000898	0.000898	CcSEcCtD
Gadobenate Dimeglumine—Asthenia—Methotrexate—esophageal cancer	0.000874	0.000874	CcSEcCtD
Gadobenate Dimeglumine—Pruritus—Methotrexate—esophageal cancer	0.000862	0.000862	CcSEcCtD
Gadobenate Dimeglumine—Diarrhoea—Methotrexate—esophageal cancer	0.000834	0.000834	CcSEcCtD
Gadobenate Dimeglumine—Dizziness—Methotrexate—esophageal cancer	0.000806	0.000806	CcSEcCtD
Gadobenate Dimeglumine—Vomiting—Methotrexate—esophageal cancer	0.000775	0.000775	CcSEcCtD
Gadobenate Dimeglumine—Rash—Methotrexate—esophageal cancer	0.000768	0.000768	CcSEcCtD
Gadobenate Dimeglumine—Dermatitis—Methotrexate—esophageal cancer	0.000767	0.000767	CcSEcCtD
Gadobenate Dimeglumine—Headache—Methotrexate—esophageal cancer	0.000763	0.000763	CcSEcCtD
Gadobenate Dimeglumine—Nausea—Methotrexate—esophageal cancer	0.000724	0.000724	CcSEcCtD
